Exicure uses its proprietary spherical nucleic acids to treat disease at its genetic source

The clinical-stage biotechnology company has pioneered the development of 3D spherical nucleic acids to treat a broad range of inflammatory disorders affecting multiple organs in the body.

Oct 25, 2016
Page of


Exicure is a clinical stage biotechnology company developing a new class of immunomodulatory and gene silencing drugs against validated targets. Its 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. Its lead programs address diseases from inflammatory disorders to oncology.

No comments yet.